CL2013003163A1 - Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion. - Google Patents

Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion.

Info

Publication number
CL2013003163A1
CL2013003163A1 CL2013003163A CL2013003163A CL2013003163A1 CL 2013003163 A1 CL2013003163 A1 CL 2013003163A1 CL 2013003163 A CL2013003163 A CL 2013003163A CL 2013003163 A CL2013003163 A CL 2013003163A CL 2013003163 A1 CL2013003163 A1 CL 2013003163A1
Authority
CL
Chile
Prior art keywords
composition
weight
amount
ibuprofen
cellulose
Prior art date
Application number
CL2013003163A
Other languages
English (en)
Inventor
Haigang Chen
Gareth Winckle
Christopher Riley
Original Assignee
Aponia Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47108054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003163(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aponia Laboratories Inc filed Critical Aponia Laboratories Inc
Publication of CL2013003163A1 publication Critical patent/CL2013003163A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición para la administración transdérmica de S-ibuprofeno o sales del mismo, que comprende: S-ibuprofeno en una cantidad de 5% en peso de la composición; un agente gelificante, en la que el agente gelificante se selecciona del grupo que consiste en metilcelulosa, etil-celulosa, hidroxicelulosa, hidroxietil-celulosa, hidroxipropil-celulosa, hidroxipropilmetilcelulosa, y mezclas de las mismas; y donde el agente gelificante está presente en una cantidad entre 0,1% y 10% en peso de la composición; miristato de isopropilo en una cantidad entre 0,1% y 10% en peso de la composición; propilenglicol en una cantidad entre 15% y 25% en peso de la composición; un alcohol alquilico inferior seleccionado entre el grupo que consiste en etanol y alcohol isopropílico o una mezcla de los mismos, en una cantidad entre 25% y 70% en peso de la composición; y agua; donde la composición tiene un pH aparente de 7,0. Uso de dicha composición para la reducción del dolor o la inflamación.
CL2013003163A 2011-05-03 2013-11-04 Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion. CL2013003163A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161482058P 2011-05-03 2011-05-03

Publications (1)

Publication Number Publication Date
CL2013003163A1 true CL2013003163A1 (es) 2014-07-04

Family

ID=47108054

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003163A CL2013003163A1 (es) 2011-05-03 2013-11-04 Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion.

Country Status (26)

Country Link
US (7) US9205041B2 (es)
EP (2) EP3560485A1 (es)
JP (1) JP5989095B2 (es)
KR (1) KR101926211B1 (es)
CN (1) CN103717213B (es)
AU (3) AU2012250664B2 (es)
BR (1) BR112013028435A2 (es)
CA (1) CA2835062C (es)
CL (1) CL2013003163A1 (es)
CO (1) CO6862148A2 (es)
CY (1) CY1122273T1 (es)
DK (1) DK2704703T3 (es)
EA (1) EA026697B1 (es)
ES (1) ES2749323T3 (es)
HR (1) HRP20191806T1 (es)
HU (1) HUE046750T2 (es)
LT (1) LT2704703T (es)
ME (1) ME03540B (es)
MX (1) MX365427B (es)
PE (2) PE20180399A1 (es)
PL (1) PL2704703T3 (es)
PT (1) PT2704703T (es)
RS (1) RS59484B1 (es)
SI (1) SI2704703T1 (es)
SM (1) SMT201900595T1 (es)
WO (1) WO2012151427A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5989095B2 (ja) 2011-05-03 2016-09-07 アポニア ラボラトリーズ インコーポレイテッド イブプロフェンの経皮組成物およびその使用方法
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
JP6632810B2 (ja) * 2015-03-31 2020-01-22 小林製薬株式会社 外用医薬組成物
US10383825B2 (en) 2015-08-13 2019-08-20 Temple University—Of the Commonwealth System of Higher Education Calcium alginate dosage formulations, and methods of making and using thereof
JP2019510824A (ja) * 2016-03-31 2019-04-18 スマーテック・トピカル・インコーポレイテッドＳＭＡＲＴＥＣＨ ＴＯＰＩＣＡＬ，Ｉｎｃ． 送達システム
GB201609968D0 (en) 2016-06-07 2016-07-20 Futura Medical Dev Ltd Topical pharmaceutical formulation
EP4218741A1 (en) * 2016-10-12 2023-08-02 Teikoku Seiyaku Co., Ltd. Water-based adhesive patch comprising ketoprofen
US20190298688A1 (en) * 2016-11-21 2019-10-03 Vivier Canada Inc. Putrescine slow-release topical formulations
GB201706969D0 (en) * 2017-05-02 2017-06-14 Medherant Ltd Formulation
JP7025129B2 (ja) * 2017-05-17 2022-02-24 小林製薬株式会社 筋痙攣治療剤
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
AU2018378072B2 (en) 2017-12-04 2024-05-23 Kenvue Brands Llc Topical emulsion composition containing nonsteroidal anti-inflammatory drug
KR20190101140A (ko) * 2018-02-22 2019-08-30 동아제약 주식회사 비스테로이드성 소염진통 활성성분을 함유하는 필름 형성 약제학적 조성물
CA3102689C (en) 2018-06-04 2023-08-29 Arcutis, Inc. Method and formulation for improving roflumilast skin penetration lag time
US20220378729A1 (en) 2019-11-06 2022-12-01 Smartech Topical, Inc. Topical formulations of cyclooxygenase inhibitors and their use
EP4458414A3 (en) 2020-12-04 2025-01-01 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having antifungal properties
JP2024540701A (ja) 2021-11-08 2024-11-01 リー・ウェイヨン 患者に薬物を送達するための経皮薬物送達システム
US12453721B2 (en) 2021-12-28 2025-10-28 Arcutis Biotherapeutics, Inc. Topical roflumilast aerosol foams
WO2024058848A1 (en) 2022-09-15 2024-03-21 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4185100A (en) 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
JPS59222409A (ja) 1983-06-01 1984-12-14 Nippon Redarii Kk 消炎鎮痛ゲル軟膏剤
GB8401965D0 (en) 1984-01-25 1984-02-29 Beecham Group Plc Composition
DE3532562A1 (de) 1985-09-12 1987-03-12 Dolorgiet Gmbh & Co Kg Transdermal resorbierbare, wasserhaltige zubereitungen von arylpropionsaeurederivaten und verfahren zur herstellung derselben
DE3669103D1 (de) 1986-11-14 1990-04-05 Puetter Medice Chem Pharm Ibuprofen enthaltendes arzneimittel.
US4916161A (en) 1988-10-25 1990-04-10 Bristol-Myers Squibb Taste-masking pharmaceutical agents
US5093133A (en) * 1990-01-24 1992-03-03 Mcneil-Ppc, Inc. Method for percutaneous delivery of ibuprofen using hydroalcoholic gel
IT1265001B1 (it) * 1993-12-16 1996-10-17 Zambon Spa Composizione farmaceutica per uso topico contenente acido (s)-2-(4- isobutilfenil) propionico
GB9404248D0 (en) * 1994-03-05 1994-04-20 Boots Co Plc Pharmaceutical formulations
US5807568A (en) * 1994-12-27 1998-09-15 Mcneil-Ppc, Inc. Enhanced delivery of topical compositions containing flurbiprofen
US5654337A (en) * 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
DE29714719U1 (de) 1997-08-19 1998-10-01 Starke, Olaf, 53940 Hellenthal Compaktdisc in Scheck oder Visitenkartenformat
US5976566A (en) * 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
US6083996A (en) * 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
JPH11199521A (ja) * 1997-12-26 1999-07-27 Lion Corp 皮膚外用剤
JP2000143540A (ja) * 1998-11-06 2000-05-23 Bristol Myers Squibb Co 非ステロイド系消炎鎮痛薬含有外用剤
US6962691B1 (en) * 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions
FR2808685B1 (fr) * 2000-05-12 2004-10-08 Sanofi Synthelabo Compositions pharmaceutiques pour administration transdermique d'agents anti-inflammatoires
NO20014746D0 (no) * 2001-09-28 2001-09-28 Clas M Kjoelberg Smertelindrende middel
AU2002341984B2 (en) * 2001-10-04 2008-01-03 Macrochem Corporation Ibuprofen salt emulsifiers and cream formulations containing same
US7816366B2 (en) * 2002-02-12 2010-10-19 Asymmetric Therapeutics, Llc Compositions and methods for treating and preventing dermatoses
WO2005051347A2 (en) 2003-10-30 2005-06-09 Dianne Elizabeth Marshall A simple process and formulation for making taste-­ masked ibuprofen liquid preparations and similar good­-tasting preparation of other pharmaceutically active or bitter, poor tasting compounds for the production of liquid preparations
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
JP2008531693A (ja) * 2005-03-03 2008-08-14 アイ エス ダブリュ グループ インコーポレイテッド 局所用ゲル組成物
US20080317684A1 (en) 2006-09-06 2008-12-25 Isw Group, Inc. Topical Compositions
WO2010039535A1 (en) * 2008-09-23 2010-04-08 Meta Cosmetics, Llc Compositions and methods to treat epithelial-related conditions
MX2010005932A (es) * 2007-11-29 2010-06-15 Alltranz Inc Metodos y composiciones para mejorar la viabilidad de poros de microaguja.
HUP0700828A2 (en) * 2007-12-20 2010-01-28 Richter Gedeon Nyrt Transdermal pharmaceutical compositions containing tolperisone alone and in combination
US20100055161A1 (en) 2008-08-27 2010-03-04 Dong June Ahn Hydrogel face mask for delivering skin care agents
RU2505291C2 (ru) * 2009-06-24 2014-01-27 СТРАТЕДЖИК САЙЕНС ЭНД ТЕКНОЛОДЖИЗ, ЭлЭлСи Топическая композиция, содержащая ибупрофен
WO2011063531A1 (en) 2009-11-27 2011-06-03 Nuvo Research Inc. Topical ibuprofen formulations
GB0921686D0 (en) * 2009-12-11 2010-01-27 Reckitt Benckiser Healthcare I Topical formulation
CA2828086C (en) 2010-03-10 2018-07-31 Nuvo Research Inc. Foamable formulation
JP5989095B2 (ja) 2011-05-03 2016-09-07 アポニア ラボラトリーズ インコーポレイテッド イブプロフェンの経皮組成物およびその使用方法

Also Published As

Publication number Publication date
AU2019203188A1 (en) 2019-05-30
CN103717213B (zh) 2016-11-09
DK2704703T3 (da) 2019-10-14
SMT201900595T1 (it) 2019-11-13
US20180125779A1 (en) 2018-05-10
JP5989095B2 (ja) 2016-09-07
PE20140936A1 (es) 2014-08-06
EA026697B1 (ru) 2017-05-31
US20240108569A1 (en) 2024-04-04
CY1122273T1 (el) 2020-11-25
CN103717213A (zh) 2014-04-09
KR20140041504A (ko) 2014-04-04
PE20180399A1 (es) 2018-02-28
SI2704703T1 (sl) 2019-12-31
LT2704703T (lt) 2019-12-10
CO6862148A2 (es) 2014-02-10
MX2013012832A (es) 2015-01-22
EP2704703B1 (en) 2019-07-24
US20220387301A1 (en) 2022-12-08
EP3560485A1 (en) 2019-10-30
KR101926211B1 (ko) 2019-02-26
US10821071B2 (en) 2020-11-03
ME03540B (me) 2020-07-20
WO2012151427A1 (en) 2012-11-08
AU2012250664A1 (en) 2013-12-19
US9849080B2 (en) 2017-12-26
AU2017204878A1 (en) 2017-08-03
HUE046750T2 (hu) 2020-03-30
EP2704703A4 (en) 2014-12-03
PL2704703T3 (pl) 2020-03-31
RS59484B1 (sr) 2019-12-31
PT2704703T (pt) 2019-10-25
JP2014513132A (ja) 2014-05-29
US20210045999A1 (en) 2021-02-18
AU2012250664B2 (en) 2017-04-20
HRP20191806T1 (hr) 2020-01-10
CA2835062C (en) 2019-08-13
US11419814B2 (en) 2022-08-23
NZ618259A (en) 2016-02-26
US9205041B2 (en) 2015-12-08
NZ703779A (en) 2016-10-28
CA2835062A1 (en) 2012-11-08
BR112013028435A2 (pt) 2017-01-24
EP2704703A1 (en) 2014-03-12
US20130005816A1 (en) 2013-01-03
EA201391623A1 (ru) 2014-06-30
US20160331678A1 (en) 2016-11-17
ES2749323T3 (es) 2020-03-19
US20230248640A1 (en) 2023-08-10
MX365427B (es) 2019-06-03

Similar Documents

Publication Publication Date Title
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
ES2553742T3 (es) Forma de dosificación farmacéutica que comprende 6'-fluor-(N-metil- o N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina
HRP20191806T1 (hr) Transdermalni pripravci ibuprofena i postupci za njihovu uporabu
ES2478264T3 (es) Glicerosomas y uso de estos en preparaciones farmacéuticas y cosméticas para aplicación tópica
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
AR084691A1 (es) Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
PE20210667A1 (es) Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
AR088381A1 (es) Formulaciones de etanercept estabilizadas con meglumina
CU20100238A7 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato
PE20141539A1 (es) Una nueva composicion terapeutica que contiene apomorfina como principio activo
CL2011000135A1 (es) Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica.
BR112014016661A2 (pt) formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma
UY31294A1 (es) Derivados de tetrahidrocarbozol, métodos para obtenerlos, formulaciones que los contienen y usos de los mismos
AR091039A1 (es) Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento
BR112015020389A8 (pt) compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos
MX2015012109A (es) Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso.
BR112015027436A8 (pt) composição tópica e veículo para administração de ingredientes farmaceuticamente ou cosmeticamente ativos
AR064263A1 (es) Composiciones farmaceuticas que comprenden un compuesto bisfosfato
ES2600316T3 (es) Sistemas distribuidores de gel para la higiene bucodental
AR073089A1 (es) DERIVADOS DE (POLI)AMINOALQUILAMINOALQUILAMIDAS, ALQUIL-UREA O ALQUILSULFONAMIDA DE EPIPODOFILOTOXINA, UN PROCESO PARA PREPARARLOS, SU APLICACIoN EN TERAPIA COMO AGENTES ANTICANCER Y COMPOSICION FARMACEUTICA QUE LOS CONTIENEN.
CL2012003119A1 (es) Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre.
MX2019008115A (es) Formulaciones topicas de detomidina.
ES2422563A1 (es) Composición farmacéutica inyectable de ibuprofeno y arginina, su procedimiento de preparación, forma de dosificación unitaria y utilización de la misma
AR086252A1 (es) Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo